Abstract:Abstract Introduction Methadone treatment for opioid use disorder (OUD) reduces drug cravings and promotes abstinence, but sleep disturbances can negatively impact OUD recovery outcomes. Irregular sleep architecture and respiratory disturbance in outpatients administered methadone as medication for OUD (MOUD) are common, but inter-individual differences may be substantial. We investigated the magnitude and stability of inter-individual differences in sleep architecture and respiratory measures in outpatients in their first 90 days of MOUD treatment. Methods N=6 adults (42.5±10.4y, four females) enrolled in local MOUD programs participated in this research study. The daily methadone dose varied between participants (75.8±23.2mg, range 50-120mg). All participants reported past use of multiple substances; four reported current mental health disorders; and four reported chronic pain. As part of the study, participants underwent two consecutive nights of cardiorespiratory PSG, with lights off at 21:49 on average (range 21:17-22:16) on both nights. Sleep stages and apnea-hypopnea index (AHI) were analyzed for systematic inter-individual differences using variance components analysis. The stability of inter-individual differences was quantified with the intraclass correlation coefficient (ICC, ranging from 0 to 1 for negligible to complete stability). Results On night one, mean±SD was 441.9±21.1min for total sleep time (TST), 9.0±5.2min for sleep latency (SL), 35.3±22.4min for wakefulness after sleep onset (WASO), 28.8±26.6min for N1, 220.8±58.6min for N2, 114.0±77.2min for N3, and 78.3±65.6min for REM. AHI scores were 16.4±9.1, indicating moderate sleep apnea on average. Compared to similarly aged healthy adults, N1 was low, and TST, WASO, N2, REM, and AHI were high. Stability was significant and substantial for N1, N2, REM, and AHI (ICC≥0.68, F≥5.19, P< 0.05). Conclusion Despite small sample size, we found substantial, stable inter-individual differences in N1, N2, REM, and AHI, whereas TST, SL, WASO, and N3 did not reach statistical significance. Varying methadone doses, prior substance use, physical and mental health, chronic pain, and (epi)genetic predisposition may partially account for these inter-individual differences. Our PSG data were collected in-laboratory, not naturalistically; results should be interpreted accordingly. Given the substantial, stable inter-individual differences in sleep architecture, a personalized approach to sleep management may be crucial to help improve OUD recovery outcomes. Support (if any) WSU ORAP and HSCL

Sleep Deficiency and Opioid Use Disorder: Trajectory, Mechanisms, and Interventions

Sleep-related impairment among people who use opioids: The critical role of structural vulnerability

Sleep behavior traits and associations with opioid-related adverse events: a cohort study

0986 Inter-Individual Differences in Sleep Architecture of Patients Receiving Methadone for Opioid Use Disorder

Circadian rhythm disruptions associated with opioid use disorder in synaptic proteomes of human dorsolateral prefrontal cortex and nucleus accumbens

Pathogenesis of sleep disordered breathing in the setting of opioid use: A multiple mediation analysis using physiology

Treatment of insomnia associated with alcohol and opioid use: a narrative review

Sleep Health among Community-Recruited Opioid-Using People Who Inject Drugs in Los Angeles, CA and Denver, CO

Sleeping Problems in Chinese Illicit Drug Dependent Subjects

Persistent sleep problems among people in recovery from substance use disorders: a mixed methods study

Spontaneous oxycodone withdrawal disrupts sleep, circadian, and electrophysiological dynamics in rats

Opioid use disorder: current trends and potential treatments

Chronic Sleep Deprivation Blocks Voluntary Morphine Consumption but Not Conditioned Place Preference in Mice

Personalized medicine and opioid use disorder

Sleep and substance use: Practice considerations for social workers

Sleep Deficiency in Obstructive Sleep Apnea

The Association Between Sleep Disturbances and Perceived Stress in Substance Use Disorder Treatment

0911 Characterizing Sleep, Pain, and Opioid Craving in People with Chronic Low Back Pain on Long Term Opioid Therapy

IUPHAR review: Recent progress in the development of Mu opioid receptor modulators to treat opioid use disorders

0194 Impact of Sleep Deprivation Combined with Alcohol or Oxycodone on Sleep Architecture in Healthy Young Adults

Disordered Sleep in Adolescents Recovering from Surgery